Rachael Tootle
Family · Richmond, TXNPI 1114235199
Payments from drug & device makers
Across 138 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$816
- AbbVie$345
- Novo Nordisk$289
- Alkermes, Inc.$234
- Sunovion Pharmaceuticals Inc.$220
- Antares Pharma, Inc.$195
- plus $861 from 21 others
What the payments were for
- Food & beverage$2,960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 27 | $816 |
| AbbVie | 19 | $345 |
| Novo Nordisk | 20 | $289 |
| Alkermes, Inc. | 9 | $234 |
| Sunovion Pharmaceuticals Inc. | 14 | $220 |
| Antares Pharma, Inc. | 8 | $195 |
| Boston Scientific | 2 | $120 |
| Shield Therapeutics Inc | 5 | $80 |
| GSK | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Indivior Inc. | 3 | $58 |
| Amgen | 3 | $53 |
| Tolmar, Inc. | 3 | $48 |
| Pfizer | 2 | $44 |
| Johnson & Johnson | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Dexcom, Inc. | 1 | $30 |
| Noven Therapeutics, LLC | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Gilead | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,960 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 22 | $28,685 |
| OzempicSemaglutide | 18 | $24,709 |
| EliquisApixaban | 18 | $16,294 |
| Atorvastatin Calcium | 130 | $870 |
| Dutasteride | 27 | $606 |
| Gabapentin | 32 | $515 |
| Levothyroxine Sodium | 82 | $492 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 26 | $396 |
| Omeprazole | 42 | $389 |
| Amlodipine Besylate | 103 | $361 |
| Valsartan | 23 | $342 |
| Metoprolol Succinate | 43 | $340 |
| Tamsulosin Hcl | 44 | $328 |
| Famotidine | 14 | $309 |
| Carvedilol | 44 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $15 | $28,68522 claims |
| Novo NordiskOzempic | $289 | $24,70918 claims |
| PfizerEliquis | $44 | $16,29418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Richmond
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.